Abbott’s Synthroid Faces Removal

The Food and Drug Administration has told the makers of Synthroid, the third most frequently prescribed drug in the U.S., that the medicine has a “history of problems” and cannot be recognized as “safe and effective.”The agency’s statements raise the possibility that the 40-year-old drug, which has never been officially approved for use by the Read more about Abbott’s Synthroid Faces Removal[…]

abbott laboratories

Idun And Abbott Extend Partnership Agreement

Idun Pharmaceuticals, Inc. has extended their worldwide research and development agreement with Abbott Laboratories focusing on the discovery and development of products to treat people with cancer. Under this agreement, Abbott and Idun will continue their collaboration to discover drugs that regulate the activity of specific proteins involved in the cell pathways leading to programmed Read more about Idun And Abbott Extend Partnership Agreement[…]

Tranxenogen Announces Collaboration With Abbott

TranXenoGen, Inc. has signed a collaborative agreement with Abbott Laboratories to evaluate TranXenoGen’s avian transgenic technology for production of a monoclonal antibody under development at the Abbott Bioresearch Center. The TranXenoGen avian transgenic technology allows for the expression of gene encoding of proteins from cells. As a result, the technology can be used for high-volume Read more about Tranxenogen Announces Collaboration With Abbott[…]

napro biotherapeutics

Napro Completes Sale Of Worldwide Paclitaxel Business To Mayne Pharma

NaPro BioTherapeutics, Inc. announced that it has completed the sale of its worldwide generic injectable paclitaxel business to Mayne Pharma for $71.7 million in cash minus an inventory adjustment of $4.6 million to reflect NaPro’s actual inventory as of the date of closing. Leonard P. Shaykin, Chairman and CEO NaPro, stated, “The net proceeds from Read more about Napro Completes Sale Of Worldwide Paclitaxel Business To Mayne Pharma[…]

abbott laboratories

Abbott Enters Agreement With Medical Analysis Systems

Abbott Laboratories has announced a co-marketing agreement with Medical Analysis Systems, Inc. (MAS), a Fisher Scientific International Inc. company, for the VecTest (TM) family of antigen-based assays, including a rapid test for detecting the West Nile virus in infected mosquitoes.The proprietary VecTest products, developed and manufactured by MAS, also include rapid tests for detecting malaria Read more about Abbott Enters Agreement With Medical Analysis Systems[…]

abbott laboratories

Collaborative Group And Abbott Sign License Agreement

The Collaborative Group, Ltd., and Abbott Laboratories have signed a worldwide, exclusive license agreement granting Abbott access to Collaborative’s technology relating to fungal beta (1,3)-glucan detection reagents for human fungal diagnostic assay development and commercialization. The technology allows easy integration with a variety of diagnostic assay formats, and also provides improved performance over other existing Read more about Collaborative Group And Abbott Sign License Agreement[…]